Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $25.69 Consensus Price Target from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average recommendation of “Hold” from the nineteen research firms that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $24.0667.

A number of analysts have weighed in on the stock. Weiss Ratings raised shares of Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. Benchmark reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Finally, Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. Tidal Investments LLC bought a new stake in Sarepta Therapeutics in the 2nd quarter valued at $183,000. Baird Financial Group Inc. boosted its position in shares of Sarepta Therapeutics by 7.6% during the 2nd quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 901 shares in the last quarter. Nykredit A S bought a new stake in Sarepta Therapeutics in the second quarter valued at about $43,000. Corient Private Wealth LP increased its stake in Sarepta Therapeutics by 273.4% in the second quarter. Corient Private Wealth LP now owns 36,712 shares of the biotechnology company’s stock valued at $660,000 after acquiring an additional 26,880 shares during the period. Finally, Amundi acquired a new position in Sarepta Therapeutics in the second quarter worth about $350,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $20.81 on Friday. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $18.71 and its two-hundred day moving average is $18.74. The company has a market cap of $2.20 billion, a P/E ratio of -7.18, a P/E/G ratio of 0.29 and a beta of 0.27. Sarepta Therapeutics has a 12 month low of $14.68 and a 12 month high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.42. The company had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.Sarepta Therapeutics’s revenue for the quarter was down 34.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.02 earnings per share. On average, equities analysts expect that Sarepta Therapeutics will post 3.53 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD.